In our cohort, all 17 patients maintained >6-week intervals between final anti-PD-1 administration and allo-HSCT, with 6 subjects receiving PTCy prophylaxis - factors potentially contributing to reduced GVHD risk. This evidence concerns the gene PDCD1 and graft versus host disease.